Your browser doesn't support javascript.
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
Cao, Yunlong; Song, Weiliang; Wang, Lei; Liu, Pan; Yue, Can; Jian, Fanchong; Yu, Yuanling; Yisimayi, Ayijiang; Wang, Peng; Wang, Yao; Zhu, Qianhui; Deng, Jie; Fu, Wangjun; Yu, Lingling; Zhang, Na; Wang, Jing; Xiao, Tianhe; An, Ran; Wang, Jing; Liu, Lu; Yang, Sijie; Niu, Xiao; Gu, Qingqing; Shao, Fei; Hao, Xiaohua; Meng, Bo; Gupta, Ravindra Kumar; Jin, Ronghua; Wang, Youchun; Xie, Xiaoliang Sunney; Wang, Xiangxi.
  • Cao Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; Changping Laboratory, Beijing 102206, China. Electronic address: yunlongcao@pku.edu.cn.
  • Song W; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China.
  • Wang L; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Liu P; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Yue C; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Jian F; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
  • Yu Y; Changping Laboratory, Beijing 102206, China; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 100050, China.
  • Yisimayi A; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China.
  • Wang P; Changping Laboratory, Beijing 102206, China.
  • Wang Y; Changping Laboratory, Beijing 102206, China.
  • Zhu Q; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Deng J; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Fu W; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
  • Yu L; Changping Laboratory, Beijing 102206, China.
  • Zhang N; Changping Laboratory, Beijing 102206, China.
  • Wang J; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China.
  • Xiao T; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; Joint Graduate Program of Peking-Tsinghua-NIBS, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
  • An R; Changping Laboratory, Beijing 102206, China.
  • Wang J; Changping Laboratory, Beijing 102206, China.
  • Liu L; Changping Laboratory, Beijing 102206, China.
  • Yang S; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China.
  • Niu X; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
  • Gu Q; Changping Laboratory, Beijing 102206, China.
  • Shao F; Changping Laboratory, Beijing 102206, China.
  • Hao X; Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
  • Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge CB2 0AW, UK.
  • Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge CB2 0AW, UK.
  • Jin R; Changping Laboratory, Beijing 102206, China; Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
  • Wang Y; Changping Laboratory, Beijing 102206, China; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 100050, China.
  • Xie XS; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; Changping Laboratory, Beijing 102206, China. Electronic address: sunneyxie@biopic.pku.edu.cn.
  • Wang X; Changping Laboratory, Beijing 102206, China; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: xiangxi@ibp.ac.cn.
Cell Host Microbe ; 30(11): 1527-1539.e5, 2022 11 09.
Artículo en Inglés | MEDLINE | ID: covidwho-2104544
ABSTRACT
Recently emerged SARS-CoV-2 Omicron subvariant, BA.2.75, displayed a growth advantage over circulating BA.2.38, BA.2.76, and BA.5 in India. However, the underlying mechanisms for enhanced infectivity, especially compared with BA.5, remain unclear. Here, we show that BA.2.75 exhibits substantially higher affinity for host receptor angiotensin-converting enzyme 2 (ACE2) than BA.5 and other variants. Structural analyses of BA.2.75 spike shows its decreased thermostability and increased frequency of the receptor binding domain (RBD) in the "up" conformation under acidic conditions, suggesting enhanced low-pH-endosomal cell entry. Relative to BA.4/BA.5, BA.2.75 exhibits reduced evasion of humoral immunity from BA.1/BA.2 breakthrough-infection convalescent plasma but greater evasion of Delta breakthrough-infection convalescent plasma. BA.5 breakthrough-infection plasma also exhibits weaker neutralization against BA.2.75 than BA.5, mainly due to BA.2.75's distinct neutralizing antibody (NAb) escape pattern. Antibody therapeutics Evusheld and Bebtelovimab remain effective against BA.2.75. These results suggest BA.2.75 may prevail after BA.4/BA.5, and its increased receptor-binding capability could support further immune-evasive mutations.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / COVID-19 Tópicos: Variantes Límite: Humanos Idioma: Inglés Revista: Cell Host Microbe Asunto de la revista: Microbiologia Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE
LILACS
LIS
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / COVID-19 Tópicos: Variantes Límite: Humanos Idioma: Inglés Revista: Cell Host Microbe Asunto de la revista: Microbiologia Año: 2022 Tipo del documento: Artículo